Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey.
Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey.
World Neurosurg. 2020 Jan;133:e529-e534. doi: 10.1016/j.wneu.2019.09.089. Epub 2019 Sep 25.
Gamma Knife radiosurgery (GKRS) outcomes for anterior clinoid process (ACP) meningiomas have not been specifically reported within any meningioma series. We present the initial and largest series in the literature that describes the presenting features, radiosurgery parameters, and radiologic and long-term clinical outcomes for 61 patients with ACP meningiomas treated with GKRS.
Medical records were reviewed for 61 consecutive patients at a single center who underwent GKRS for ACP meningioma between 2008 and 2016.
Of 61 patients with ACP meningiomas, 49 (80%) were treated with GKRS as primary treatment, and 12 (20%) were treated with GKRS as an adjuvant therapy. Before GKRS, 29 patients presented with visual impairment and 50 patients presented with headache. Median patient age was 54.9 years. Median tumor volume was 3.2 cm, and median margin dose was 12.0 Gy. The median radiologic follow-up time after GKRS was 75 months. During follow-up, tumor volume regressed in 37 cases (61%) and remained unchanged in 24 cases (39%). None of the patients experienced tumor volume progression. Tumor volume <3 cm was an independent predictor of tumor volume regression after GKRS (univariate analysis, P = 0.047; multivariate analysis, P = 0.049). Of 29 patients who presented with visual impairment, 16 (55%) improved after GKRS. None of the 61 patients developed new neurologic deficits after GKRS.
GKRS provides a high rate of tumor volume control for ACP meningiomas as well as a low complication rate. Excellent tumor volume control was associated with smaller tumor size only.
伽玛刀放射外科(GKRS)治疗前床突脑膜瘤的结果尚未在任何脑膜瘤系列中专门报道。我们报告了文献中最初也是最大的系列,该系列描述了 61 例前床突脑膜瘤患者的临床表现、放射外科参数以及放射学和长期临床结果,这些患者均接受了 GKRS 治疗。
对 2008 年至 2016 年期间在单一中心接受 GKRS 治疗的 61 例连续前床突脑膜瘤患者的病历进行了回顾性分析。
61 例前床突脑膜瘤患者中,49 例(80%)作为原发性治疗接受 GKRS 治疗,12 例(20%)作为辅助治疗接受 GKRS 治疗。在 GKRS 治疗前,有 29 例患者出现视力障碍,50 例患者出现头痛。患者中位年龄为 54.9 岁。肿瘤中位体积为 3.2cm,中位边缘剂量为 12.0Gy。GKRS 后中位放射学随访时间为 75 个月。随访期间,37 例(61%)肿瘤体积缩小,24 例(39%)肿瘤体积无变化。无一例患者出现肿瘤体积进展。肿瘤体积<3cm 是 GKRS 后肿瘤体积缩小的独立预测因素(单因素分析,P=0.047;多因素分析,P=0.049)。在 29 例出现视力障碍的患者中,16 例(55%)在 GKRS 后得到改善。61 例患者在 GKRS 后均未出现新的神经功能缺损。
GKRS 为前床突脑膜瘤提供了较高的肿瘤体积控制率和较低的并发症发生率。仅与肿瘤体积较小相关时,GKRS 可获得良好的肿瘤体积控制效果。